Our firm is about people. That is our motto and that will always be our reality.
We do our best to get to know our clients, understand their situations, and get them the compensation they deserve.
At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.
Without our team, we would’nt be able to provide our clients with anything close to the level of service they receive when they work with us.
The TorHoerman Law Team commits to the sincere belief that those injured by the misconduct of others, especially large corporate profit mongers, deserve justice for their injuries.
Our team is what has made TorHoerman Law a very special place since 2009.
The Abbott FreeStyle Libre 3 lawsuit investigation centers on allegations that defective Libre 3 and Libre 3 Plus sensors produced dangerously inaccurate glucose readings, contributing to severe hypo- and hyperglycemic events, hospitalizations, and deaths.
Lawsuits allege that Abbott did not adequately design and validate the sensors, failed to act promptly on internal and post-market safety data, and did not provide timely, clear warnings to users and clinicians about the risk of dangerously inaccurate readings.
TorHoerman Law is actively reviewing claims involving the FreeStyle Libre 3.
The FreeStyle Libre 3 and FreeStyle Libre 3 Plus are continuous glucose monitoring systems, medical devices designed to provide real-time sensor readings as an alternative to frequent blood glucose meter checks for people living with diabetes.
By relying on these sensor readings to guide insulin dosing and other daily decisions, many users depend on the devices to avoid wrong treatment decisions that could destabilize their blood sugar levels.
However, Abbott has issued a recall and medical device corrections for certain Libre 3 and Libre 3 Plus sensors that may be defective, leaving millions of potentially affected devices at the center of regulatory and legal concern.
Lawsuits concerning the FreeStyle Libre 3 and Libre 3 Plus systems are rising due to claims that defective sensors caused inaccurate glucose readings, linked to hundreds of serious injuries and at least seven deaths worldwide.
As of early 2026, Abbott has reported 860 serious injuries and seven deaths globally associated with inaccurate readings from FreeStyle Libre sensors, figures that now play a central role in ongoing investigations and claims.
Reported injuries include severe hypoglycemia, diabetic ketoacidosis (DKA), seizures, loss of consciousness, permanent neurological damage, and wrongful death allegedly linked to faulty glucose readings generated by the sensors.
When incorrect low glucose readings occur, users may consume unnecessary carbohydrates, skip or delay insulin doses, or otherwise alter their regimen in ways that increase the risk of acute metabolic crises and other adverse reactions.
Individuals who receive recall notices are often instructed to immediately discontinue use of the affected sensor and contact their health care team, and many who suffered serious complications or lost a family member have begun filing lawsuits to challenge Abbott over the alleged defects in these medical devices.
If you or a loved one used a FreeStyle Libre 3 or FreeStyle Libre 3 Plus sensor and later experienced severe hypoglycemia, diabetic ketoacidosis, hospitalization, or a suspected Libre-related death, you may be eligible to pursue a FreeStyle Libre 3 lawsuit.
Contact TorHoerman Law for a free consultation.
You can also use the chat feature on this page to find out if you qualify for legal action.
The FreeStyle Libre 3 is a continuous glucose monitor in Abbott’s family of Libre products, designed to provide real-time interstitial glucose readings for people living with diabetes.
The system includes a small, disposable sensor worn on the back of the upper arm and a sensor applicator that inserts a tiny filament just under the skin.
The Libre 3 sensor continuously measures glucose levels and sends data to a compatible smartphone app or reader, allowing users to see current glucose values, trends, and alerts without routine fingerstick checks from a blood glucose meter in most situations.
Abbott markets Libre 3 as the smallest and thinnest sensor in the Libre line, intended to be worn for up to 14 days at a time while the user goes about normal daily activities.
As with other Libre products, the device is meant to help users and clinicians track patterns and make informed decisions about insulin dosing, diet, and activity.
When the device functions properly, users are instructed to compare the sensor readings with how they feel and contact a health care professional if the values do not match symptoms or expectations.

In safety notices and recall communications, Abbott and regulators have advised some Libre 3 users to discontinue use and dispose of affected sensors when lot numbers fall within the impacted ranges.
Those instructions typically direct users to stop using the affected sensor, discard it safely, and request a replacement while consulting their health care team about alternative glucose monitoring.
Although the Libre 3 is cleared as a medical device for adults and children over a certain age, its usefulness depends on accurate readings, appropriate alarms, and careful integration into an overall diabetes management plan.
The FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems are continuous glucose monitoring setups that combine a small disposable sensor, a sensor applicator, and a compatible smartphone app or reader to track glucose levels throughout the day.
The sensor is applied to the back of the upper arm with the sensor applicator, which inserts a tiny filament just under the skin to measure glucose in the interstitial fluid.
Once activated, the sensor automatically sends glucose readings at regular intervals to the user’s phone or reader via Bluetooth, creating a continuous stream of data rather than isolated fingerstick results.
Users can view real-time glucose values, trend arrows, and historical graphs, and in many cases receive alarms when levels are rising or falling rapidly or crossing preset thresholds.
These systems are designed so that most treatment decisions can be based on sensor data instead of routine blood glucose meter checks, though users are still instructed to confirm readings with a meter if values do not match symptoms.
Libre products are typically worn for up to 14 days per sensor, after which the sensor is removed and replaced to maintain accurate, continuous monitoring.

Functions of the FreeStyle Libre 3 and Libre 3 Plus systems include:
FreeStyle Libre 3 devices are used by people with diabetes who need frequent glucose checks and want a continuous alternative to traditional fingerstick testing.
They are prescribed for both Type 1 and Type 2 diabetes, including adults and children, when a clinician determines that real-time glucose data will help manage insulin, diet, and activity more safely.
Caregivers and family members may also use connected apps to monitor sensor data remotely for loved ones who are at higher risk of dangerous highs or lows.
People who may use FreeStyle Libre 3 devices include:
The FreeStyle Libre 3 recall involves a series of safety actions targeting certain FreeStyle Libre 3 and Libre 3 Plus sensors after reports of incorrect glucose readings in people relying on the devices for daily diabetes management.
Abbott’s most recent and most significant action is a Class I recall for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors, where internal testing determined that a manufacturing issue could cause the sensor to report falsely low glucose values.
Regulators have explained that a potentially affected sensor may show dangerously low readings even when a user’s blood sugar is normal or high, leading patients and clinicians to trust data that does not match the person’s actual condition.
Abbott and the FDA have disclosed hundreds of serious injuries and at least seven deaths worldwide linked to these issues, with many additional reports of hospitalizations and other less serious complications associated with the recalled devices.
When users act on these incorrect glucose readings, they may eat excessive carbohydrate intake, skip or delay insulin doses, or make other incorrect treatment decisions that can trigger severe hypoglycemia, diabetic ketoacidosis, and long-term harm.
Earlier recall and correction notices for certain FreeStyle Libre 3 sensors, along with separate actions involving other Libre family sensors such as older Libre readers with battery and accuracy issues, have contributed to a broader picture of recurring quality problems in this product line.
Because many people wear these sensors continuously for an extended period, an undetected defect can expose a user to repeated inaccurate readings and compounding risks over days or weeks.
In recall and field safety notices, Abbott and regulators have advised users with a potentially impacted or potentially affected sensor to discontinue use and dispose of the device in line with instructions, then switch to alternative monitoring while consulting their health care team.

Facts about the FreeStyle Libre 3 recall include:
The recall applies to defined model numbers and unique device identifiers for FreeStyle Libre 3 and Libre 3 Plus sensors, and users are instructed to verify their devices through Abbott’s FreeStyleCheck resources or their pharmacy notices.
Abbott has emphasized that unaffected sensors and other Libre family sensors can continue to be used as directed, but patients should double-check serial numbers and speak with their clinicians if they are unsure.
For many families, recall letters, pharmacy notifications, and national coverage of the Class I recall were the first signals that a device they relied on might pose serious health risks.
These recall facts now sit at the center of FreeStyle Libre 3 lawsuit investigations, where plaintiffs argue that Abbott did not address the quality problems quickly enough to prevent avoidable injuries and deaths.
The FreeStyle Libre 3 recall specifically targets certain sensor models and associated identifiers, rather than every Libre device on the market.
Regulators and Abbott have identified particular model numbers and unique device identifiers (UDI-DI) as part of the recall, and have provided a detailed lot-code list so users and distributors can confirm whether individual sensors are affected.

Devices, model numbers, and identifiers included in the recall include:
FreeStyle Libre 3 lawsuits focus on claims that defective Libre 3 and Libre 3 Plus sensors produced dangerously inaccurate glucose readings, leading to potential injury and death for people who relied on the devices to manage diabetes.
Plaintiffs allege that incorrect low readings caused users to delay insulin doses, take in unnecessary carbohydrates, or otherwise make treatment decisions that left them severely hyperglycemic, sometimes progressing to diabetic ketoacidosis (DKA), coma, or wrongful death.
Public data from Abbott and the U.S. Food and Drug Administration indicate that, as of early 2026, at least 860 serious injuries and seven deaths worldwide have been linked to inaccurate FreeStyle Libre sensor readings, including FreeStyle Libre 3 and Libre 3 Plus devices.
In addition to these severe outcomes, lawsuits and investigations describe hospitalizations, seizures, loss of consciousness, and permanent neurological injuries following episodes where users allegedly followed faulty sensor data.
One wrongful death complaint filed in California, for example, alleges that a Libre 3 Plus device reported a dangerously low glucose value while the user’s actual blood glucose was extremely high, contributing to a fatal cardiac event.

Separate from personal injury cases, at least one proposed class action seeks economic damages for consumers who purchased Libre 3 sensors that were later recalled or found to be defective, arguing they overpaid for a product that did not perform as advertised.
Across these cases, claims commonly include strict product liability, negligence, failure to warn, and breach of warranty, all centered on whether Abbott adequately designed, tested, monitored, and corrected Libre 3 sensor problems.
People who suffered severe hypo- or hyperglycemic events, DKA, hospitalization, or the loss of a loved one are encouraged to explore a potential injury or wrongful death claim related to recalled Libre 3 sensors.
Because the litigation is still in its early stages, with limited filed cases and no consolidated multidistrict litigation yet established, the landscape may change as more injured users come forward and courts evaluate these allegations.
People may qualify for a FreeStyle Libre 3 lawsuit if they used a FreeStyle Libre 3 or FreeStyle Libre 3 Plus sensor that falls within the recalled or potentially defective product groups and then experienced a serious medical event.
In personal injury cases, lawyers are generally looking for clear links between inaccurate sensor readings and outcomes such as hospitalization, emergency treatment, or lasting health problems.
Wrongful death claims may be considered when a person with diabetes died after relying on Libre 3 sensor readings that appear inconsistent with later lab work, autopsy findings, or hospital records.
Eligibility will also depend on medical records, device details, and whether the claim is filed within the applicable statute of limitations in the state where the injury occurred.

People who may qualify for a FreeStyle Libre 3 personal injury or wrongful death lawsuit often include:
Evidence in a FreeStyle Libre 3 case should clearly show that the person was using a Libre 3 or Libre 3 Plus sensor and what happened medically after they relied on the sensor’s readings.
It is especially useful when records document the sensor readings, the treatment decisions made in response, and objective testing or hospital records that later revealed a different glucose level or condition.
Documentation that connects the device to a recall or safety notice can also help establish that the sensor may have been defective at the time of the injury.

Useful evidence for a FreeStyle Libre 3 claim can include:
In medical device lawsuits, “damages” refers to the full range of losses that a person or family has suffered, from medical bills and lost income to long-term disability and the impact of a wrongful death.
Lawyers assess these damages by reviewing medical records, billing statements, employment and tax records, and expert opinions about future care needs or reduced earning capacity.
They also look at the human impact of the injury, including pain, limitations on daily life, and the emotional and financial strain on spouses and family members.
In a FreeStyle Libre 3 lawsuit, all of this information may be used to advocate for compensation that reflects both the immediate harm and the long-term consequences of a defective sensor.

Potential compensation in a FreeStyle Libre 3 lawsuit may include:
TorHoerman Law is closely tracking the FreeStyle Libre 3 and Libre 3 Plus recalls and investigating claims that inaccurate sensor readings contributed to severe injuries and deaths.
Our team reviews medical records, device information, and recall documentation to help individuals and families understand whether a defective sensor may have played a role in a medical crisis or loss.

If you or a loved one experienced severe hypoglycemia, DKA, hospitalization, or a suspected Libre-related wrongful death after using a FreeStyle Libre 3 device, you can speak with TorHoerman Law about your legal options.
Contact TorHoerman Law for a free, no-obligation case evaluation to discuss your circumstances and whether a FreeStyle Libre 3 lawsuit may be appropriate in your situation.
Inaccurate FreeStyle Libre 3 sensor readings, especially falsely low or high values, can lead to treatment choices that push blood sugar into dangerous ranges.
When insulin doses are changed, delayed, or skipped based on faulty data, people with diabetes may face both immediate emergencies and long-term complications.
These events can be life-threatening and may require emergency care, hospitalization, or intensive care support.
Health risks linked to inaccurate Libre 3 readings may include:
In November 2025, the FDA classified the recall of certain FreeStyle Libre sensors as a Class I recall, its most serious category, because inaccuracies in glucose readings can lead to severe health consequences.
In July 2024, Abbott had already recalled certain lots of FreeStyle Libre 3 sensors for providing falsely high glucose readings, which could contribute to inappropriate insulin dosing and dangerous blood sugar swings.
The FDA then issued a warning letter to Abbott in January 2026, citing serious manufacturing and quality system violations at the company’s California facility and directing Abbott to address those issues.
Despite these actions, Abbott reports that it continues to produce Libre 3 and Libre 3 Plus sensors to fulfill replacement and new orders, does not expect significant supply disruptions, and will replace any potentially affected sensors at no charge.
Because Abbott has committed to providing sensors to fulfill replacement requests for recalled products, some users may expect significant supply disruptions or delays when trying to swap out affected devices.
When you call Abbott customer service, a customer service representative will typically ask for your sensor serial number and other information from the packaging to confirm whether your sensor is part of the recall.
If your device is affected, Abbott may arrange for replacement sensors to be shipped and may instruct you on how to safely continue monitoring your glucose in the meantime, which can include using a blood glucose meter or your existing FreeStyle Libre 3 reader with non-recalled sensors.
If you experience long wait times or shipping delays, it can help to keep detailed notes of your calls, reference numbers, and which sensors or supplies you were promised so your health care team and legal counsel can understand how the recall affected your care.
To find out whether your current or unused FreeStyle Libre 3 or Libre 3 Plus sensor is potentially affected, visit Abbott’s verification site at www.FreeStyleCheck.com and select “CONFIRM SENSOR SERIAL NUMBER,” then enter the number from your sensor label or box.
If your sensor is listed as affected, follow the instructions provided on the site and from your health care team about replacement and ongoing monitoring.
Affected customers are advised to use a traditional blood glucose meter, or the built-in meter in the FreeStyle Libre 3 reader, to make treatment decisions any time sensor readings do not match symptoms or expectations.
Abbott biowearables such as the FreeStyle Libre 3 use a small sensor worn on the arm together with a smartphone app or FreeStyle Libre 3 reader to deliver both glucose data and system status information.
The Libre app or reader displays current glucose, trend arrows, and alerts, but it also shows system status messages when there is a problem with the sensor, signal, or built-in meter functions, prompting users to check their equipment, review instructions, or confirm results with a traditional blood glucose meter if the readings do not match how they feel.
Owner & Attorney - TorHoerman Law
Here, at TorHoerman Law, we’re committed to helping victims get the justice they deserve.
Since 2009, we have successfully collected over $4 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.
In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.
In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.
In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.
In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
Here, at TorHoerman Law, we’re committed to helping victims get the justice they deserve.
Since 2009, we have successfully collected over $4 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?